Skip to Content
Biotechnology

Dozens of volunteers will be deliberately infected with covid-19 in the UK

The first human challenge trial should help speed up coronavirus vaccine development—but it carries obvious risks
October 20, 2020
Pexels

The news: Young, healthy people will be deliberately infected with covid-19 in the first ever human challenge trial, set to begin at a London hospital in January. The study, announced today, will recruit up to 50 healthy volunteers between 18 and 30. The UK government has pledged to invest £33.6 million ($44 million) in the trial, which will be carried out in partnership with hVIVO, a company with experience in human viral challenge trials. It will take place at the Royal Free London NHS Foundation Trust, if it gets ethical and regulatory approval. Volunteers will be paid, isolated for the duration of the study, and monitored for up to a year afterwards to check for any side effects. 

Why do this? The hope is that this trial will make it easier to closely study the disease, with the aim of speeding up the development of a vaccine. In the first phase of the trial, researchers would try to work out the smallest level of exposure required for someone to catch covid-19. Next, they could test if a vaccine prevents infection. They could also explore other potential treatments, and study the immune response. The benefit of this approach is that it lets researchers study vaccine candidates side by side to see which is the most effective. “Deliberately infecting volunteers with a known human pathogen is never undertaken lightly,” said Peter Openshaw, an investigator on the study at Imperial College London, in a statement. “However, such studies are enormously informative about a disease, even one so well studied as covid-19. It is really vital that we move as fast as possible towards getting effective vaccines and other treatments for covid-19, and challenge studies have the potential to accelerate and de-risk the development of novel drugs and vaccines.” 

Controversial: There are obvious risks to this approach. The volunteers could become seriously ill and even die. There are huge trials under way to test treatments and vaccines in people who are already infected with covid-19 naturally. And given that the challenge study doesn’t start until January, we may already be close to having an effective vaccine by then. 

Deep Dive

Biotechnology

Sam Altman invested $180 million into a company trying to delay death

Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.

Forget designer babies. Here’s how CRISPR is really changing lives

The gene-editing tool is being tested in people, and the first treatment could be approved this year.

More than 200 people have been treated with experimental CRISPR therapies

But at a global genome-editing summit, exciting trial results were tempered by safety and ethical concerns.

Three-parent baby technique could create babies at risk of severe disease

The approach was designed to prevent mitochondrial disease, but new evidence shows it might not work as planned.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.